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Background: The vast majority of patients with HER2-positive metastatic breast cancer (MBC) treated with
trastuzumab eventually develop resistance to this agent. There is an unmet need therefore, for identifying biological
markers with possible prognostic/predictive value in such patients. The aim of this study was to investigate the
prognostic role of topoisomerase II alpha gene (TOP2A) amplification and protein (TopoIIa) expression in patients
treated with trastuzumab-containing regimens.
Methods: Formalin-fixed paraffin-embedded tumor tissue samples were retrospectively collected from 225 eligible
patients treated with trastuzumab. Protein expression of ER, PgR, Ki67, PTEN, HER2 and TopoIIa were centrally
assessed by immunohistochemistry. HER2 and TOP2A gene amplification was evaluated by fluorescence in situ
hybridization. PIK3CA mutations were identified by single nucleotide polymorphism genotyping. Survival was
evaluated from the initiation of trastuzumab as 1st line treatment to the date of last follow-up or death.
Results: Among the 225 samples analyzed, only 137 (61%) were found to be HER2-positive. TOP2A was amplified in
41% and deleted in 16% of such tumors. TOP2A gene amplification was more frequent in ER-negative tumors.
TopoIIa protein expression was observed in the majority (65%) of the samples and was associated with ER-positive
status, high Ki67 expression, presence of PTEN protein and PIK3CA mutations. Median follow-up for patients treated
in the 1st line was 51 months. Survival was more prolonged with trastuzumab-containing treatment in
HER2-positive patients (50 months, log-rank, p=0.007). TOP2A non-amplified or deleted tumors were associated with
increased risk for death compared to TOP2A amplified tumors (HR=2.16, Wald’s p=0.010 and HR=2.67, p=0.009,
respectively). In multivariate analysis, a significant interaction of TOP2A with anthracycline treatment (either in the
adjuvant or the 1st line setting) was observed for survival (Wald’s p=0.015). Among the TOP2A amplified subgroup,
anthracycline-treated patients were associated with decreased risk for death.
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Conclusions: TOP2A gene amplification was shown to be a favorable prognostic marker in HER2-positive MBC
patients treated with trastuzumab, such an effect however, appears to rather be related to treatment with
anthracyclines (predictive marker for benefit from anthracyclines). The results of the present retrospective study
warrant validation in larger cohorts of patients treated in the context of randomized trials.
Keywords: Breast cancer, Topoisomerase II alpha, Fluorescence in situ hybridization, Gene amplification,
Trastuzumab, Prognostic factors, Anthracyclines, Predictive factorsBackground
Metastatic breast cancer (MBC) is an incurable disease.
Chemotherapy or hormonal therapy mainly has a pallia-
tive role, although newer agents may contribute to a
significant prolongation of survival [1,2]. HER2, a proto-
oncogene located on chromosome 17q21.1, is amplified
in approximately 20% of breast cancers and is associated
with a number of adverse prognostic factors, such as
axillary node involvement, advanced stage, hormone
receptor (HR)-negativity and increased proliferation in-
dices [3,4]. Trastuzumab (HerceptinW, Genentech, San
Francisco, CA), a recombinant humanized monoclonal
antibody against the HER2 protein, was found to pro-
long progression-free survival (PFS) and overall survival
(OS) of patients with MBC and HER2 gene amplification
or HER2 protein overexpression [5,6].
Nevertheless, it has become evident from numerous
clinical trials that a considerable number of patients with
MBC do not benefit from the administration of trastuzu-
mab, either as a single agent or in combination with
other systemic treatments. Moreover, in almost all
patients who initially respond to trastuzumab-based
treatments, tumor progression is eventually expected to
occur. On the other hand, it is conceivable that any
given targeted treatment is cost-effective only when it
is administered exclusively to those patients who will
derive the greatest benefit from it, sparing all other
patients from unnecessary side effects. Therefore, there
is an imperative need for identifying biological markers
that will predict which patients are most likely to
respond to trastuzumab-based treatments.
The topoisomerase II alpha gene (TOP2A) is located
telomerically to HER2 at 17q21-q22 and encodes for
topoisomerase II alpha (TopoIIa), a 170-kd cell cycle
regulated protein [7]. The TOP2A gene is considered to
be within the HER2 amplicon [8], although it is not
included in the “smallest region of amplification” [9] and
may follow a different fate than HER2 in terms of copy
number alterations [10]. Topoisomerases II are consid-
ered to be targets of anthracyclines [11], while TOP2A
gene amplification has been linked to anthracycline sen-
sitivity in patients with advanced breast cancer [12,13]
or in patients with high-risk primary breast cancer
receiving adjuvant chemotherapy [14-16] (reviewed in[17]). On the other hand, the predictive value of TOP2A
has been refuted by several retrospective studies [18-20]
however, flaws in the statistical design and the methodo-
logical approaches used in these studies undermine the
credibility of such opinions. In fact, a number of investi-
gators believe that TopoIIa protein expression is more
relevant than TOP2A gene status in predicting response
to anthracyclines [21].
It is noteworthy, that although extensive research
efforts have been devoted to the evaluation of the poten-
tial predictive role of TOP2A gene status with respect to
anthracycline responsiveness, little attention has been
paid to TOP2A gene alterations with regard to the out-
come of breast cancer patients following treatment with
trastuzumab in advanced stages. The main objectives of
the present study were to explore the impact of TOP2A
gene status and TopoIIa protein expression on the out-
come of MBC patients treated with trastuzumab-
containing regimens and their possible interaction with
anthracycline-containing treatment. The study was retro-
spective in nature and was performed on archival tissue
material (formalin-fixed paraffin-embedded, FFPE) from
our Group’s Tumor Repository. In addition, based on the
adverse prognostic effect of PIK3CA mutations and
PTEN protein loss in the same patient cohort, as previ-
ously shown [22], we investigated the association of these
parameters with TOP2A gene and protein status.
Patients and methods
The medical records of all patients with MBC treated
with trastuzumab-based regimens, between December
1998 and January 2010, were retrospectively reviewed.
Eligibility criteria for this study were a: histologically
confirmed MBC; b: adequacy of clinical data on patient’s
history, demographics, tumor characteristics, treatment
details (drug dosages, schedule of administration, serious
toxicities) and clinical outcome; c: availability of adequate
FFPE tumor tissue for biological marker evaluation; and
d: trastuzumab-based treatment for metastatic disease.
The translational research protocol was approved by the
Bioethics Committee of the Aristotle University of Thes-
saloniki School of Medicine (Protocol # 4283; Jan 14,
2008) under the general title “Investigation of major
mechanisms of resistance to treatment with trastuzumab
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included in the study after 2005 provided written informed
consent for the provision of biological material for future
research studies before receiving any treatment. Waiver of
consent was obtained from the Bioethics Committee for
patients included in the study before 2005.
Tissue Material
FFPE tumor tissue samples were retrospectively col-
lected from 246 breast cancer patients treated with
trastuzumab-based regimens in the metastatic setting.
Twenty-one cases were excluded for inadequate FFPE
tumor tissue, thus decreasing the number of eligible/eva-
luable patients to 225. A REMARK diagram for the
translational research studies is provided in Figure 1.
Representative hematoxylin-eosin stained sections from
the tissue blocks were reviewed by a pathologist (M.B.).
The most representative tumor areas were marked for
the construction of tissue microarray (TMA) blocks, as
previously described [22]. Each TMA block also con-
tained cores from various neoplastic, non-neoplastic
and reactive tissues serving as assay controls. Cases
not represented, damaged or inadequate on the TMA
sections were re-cut from the original blocks and these
sections were used for protein and gene analysis.
Immunohistochemistry (IHC)
Immunohistochemical labeling was performed according
to standard protocols on serial 2.5 μm thick sections
from the original blocks or the TMA blocks. All cases
were also stained for vimentin (clone V9, Dako,Figure 1 REMARK diagram. FFPE tissue availability in the present study fo
determination of HER2 and TOP2A gene amplification status and HER2 andGlostrup, Denmark) and cytokeratin 8/18 (clone 5D3,
Novocastra™, Leica Biosystems, Newcastle, U.K), which
were used as control stains for tissue immunoreactivity
and fixation, as well as identification of tumor cells. Tis-
sue samples negative for the above antibodies were
excluded from the study. The staining procedures for es-
trogen receptor (ER, clone 6F11, Novocastra™, Leica
Biosystems), progesterone receptor (PgR, clone 1A6,
Novocastra™, Leica Biosystems), HER2 (A0485 poly-
clonal antibody, Dako) and Ki67 (clone MIB-1, Dako)
were performed using a Bond Max™ autostainer (Leica
Microsystems, Wetzlar, Germany), as previously described
[23]. TopoIIa protein expression was evaluated using the
KiS1 monoclonal antibody (Dako), as previously described
[24] with slight modifications (antibody dilution: 1:200;
detection system: Envision™, Dako). PTEN (phosphatase
and tensin homologue deleted on chromosome 10) pro-
tein expression was evaluated using the 6H2.1 monoclo-
nal antibody (Dako), as previously described [25]. The
evaluation of all IHC sections was done by experienced in
breast cancer pathologists (M.B. and A.B.), blinded as to
the patients’ clinical characteristics and survival data. To
assure optimal immunoreactivity, the sections of the
TMA blocks were stained in one run for each antibody,
shortly after mounting of the TMA sections on positively
charged glass slides.
Interpretation of the IHC results
ER and PgR, HER2, Ki67 and PTEN immunostaining
was evaluated according to existing established criteria
[26-29], as previously described [22]. Briefly, ER and PgRr the application of different analytical techniques for the
TopoIIa protein expression is presented in detail.
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400) and were considered positive if staining was present
in ≥1% of tumor cell nuclei [26]; HER2 protein expres-
sion was scored in a scale from 0 to 3+, the latter corre-
sponding to uniform, intense membrane staining in
>30% invasive tumor cells [27]; for Ki67, the expression
was defined as low (<14%) and high (≥14%) based on the
percentage of stained/unstained nuclei from the tumor
areas [28]; and, PTEN protein expression (cytoplasmic,
nuclear or both) was evaluated according to a stain-
ing intensity scale from 0 (negative, no staining) to 3
(intense staining), whereby tumors with PTEN scores of
0 or 1 were considered to have PTEN loss [29]. For
TopoIIa immunostaining, a tumor was considered to be
positive if moderate to intense nuclear staining was
detected in >5% of tumor cells [30].
Fluorescence in situ hybridization (FISH)
TMA sections or whole sections (5 μm thick) were cut
for FISH analysis, using the ZytoLightW SPEC HER2/
TOP2A/centromere 17 (CEN17) triple color probe kit
(ZytoVision, Bremerhaven, Germany). FISH was per-
formed according to the manufacturer’s protocol with
minor modifications. Four carcinoma cell lines (MDA-
MB-231, MDA-MB-175, MDA-MB-453 and SK-BR-3)
from the Oracle HER2 Control Slide (Leica Biosystems),
with a known HER2 gene status, were also used as a
control of the FISH assays and analyzed for HER2 and
TOP2A genomic status.
FISH evaluation
For all probes, sequential (5 planes at 1.0 μm) digital
images were captured using the Plan Apo VC 100x/1.40
oil objective (Nikon, Japan) using specific filters for each
probe. The resulting images were reconstructed using
specifically developed software for cytogenetics (XCyto-
Gen, ALPHELYS, Plaisir, France). For the evaluation of
HER2/TOP2A/CEN17 status, non-overlapping nuclei
from the invasive part of the tumor were randomly
selected, according to morphological criteria using DAPI
staining, and scored (M.B.). The virtual slides of HER2,
ER or PgR stains, created as previously described [31],
were used for selecting the invasive part of the tumor in
each TMA. Twenty tumor nuclei were counted accord-
ing to Press et al. [13]. The HER2 gene was considered
to be amplified when the ratio of the respective gene
probe/centromere probe was ≥2.2 [27] and deleted when
the ratio was <0.75. The TOP2A gene was considered to
be amplified when the ratio of the respective gene
probe/CEN17 probe was ≥2.0 and deleted when the ratio
was <0.8 [32]. In cases with values at or near the cut-off
(1.8-2.2 for amplifications and 0.7-0.9 for deletions),
additional 20 or 40 nuclei were counted and the ratio
was recalculated. In cases with a borderline ratio at 60nuclei, additional FISH assays were performed in whole
sections. All primary image data of the TMA and whole
tumor sections have been digitally scanned and made
publicly available at: http://www.hecog-images.gr/read-
Dir.php?nextdir=TOP2AtrastuzumabMBC.
Single nucleotide polymorphism (SNP) genotyping for
PIK3CA mutations
DNA was extracted from 182 FFPE whole tissue sections
or macrodissected tissue fragments containing >70%
tumor cells, using a fully automated isolation method
based on silica-coated magnetic beads (Versant Tissue
Preparation Reagents, Siemens Healthcare Diagnostics,
Tarrytown, NY) in combination with a liquid handling
robot, as previously described [33]. Mutation testing for
PIK3CA E542K and E545K (exon 9) and H1047R (exon
20) was accomplished with custom Taqman-MGB-SNP
genotyping assays (duplex q-PCR for the detection of
control DNA and mutant target in the same reaction),
as previously described [22].
Statistical analysis
Data on selected patient and tumor characteristics, pre-
vious and subsequent lines of treatment, disease pro-
gression, events and survival were obtained from
medical records and entered into a central database.
Follow-up information was updated in February 2010.
Associations between the examined markers were per-
formed in the total cohort using the chi-square or Fish-
er’s exact tests where appropriate. The majority of
patients received trastuzumab in the 1st line of treat-
ment for metastatic disease and thus time to progression
(TTP) was defined as the time from trastuzumab initi-
ation in the 1st line of treatment (with or without
concurrent chemo/hormonal therapy) to the date of
documented disease progression. Survival was measured
from the initiation of trastuzumab treatment in patients
receiving trastuzumab as a 1st line treatment to the date
of death. Patients alive were censored at the date of the
last follow-up contact. Survival probabilities were esti-
mated by the Kaplan-Meier method and compared using
the log-rank test. For the univariate and multivariate
analyses, Cox proportional hazards models were used.
Univariate analyses were performed separately in HER2-
positive and HER2-negative patients, while multivariate
analyses were performed in the total cohort and in the
population of clinical interest, i.e. the HER2-positive
patients. Interaction tests for the examined markers
(TOP2A gene status and TopoIIa protein expression)
with HER2 and ER/PgR status were performed. We also
examined the interaction of the examined markers with
anthracycline-containing treatment in the adjuvant and/
or the 1st line metastatic setting. In the multivariate set-
ting, model choice was performed using backward
Table 1 Selected patient and tumor characteristics (at





Median (range) 54.6 (28.4-95.0) 58.9 (31.8-78.8)
N (%) N (%)
Menopausal status
Premenopausal 43 (31.4) 26 (29.5)
Postmenopausal 94 (68.6) 62 (70.5)
Performance status
0 96 (70.1) 56 (63.6)
1 28 (20.4) 18 (20.5)
2 5 (3.6) 7 (8.0)
Unknown 8 (5.8) 7 (7.8)
History of adjuvant CT 75 (54.7) 55 (62.5)
Anthracycline containing 59 (43.1) 29 (33.0)
Taxane containing 36 (26.3) 17 (19.3)
CMF-like 42 (30.7) 30 (34.1)
History of adjuvant HT 61 (44.5) 42 (47.7)
History of adjuvant RT 52 (38.0) 33 (37.5)
Tumor grade (initial diagnosis)
1 4 (2.9) 2 (2.3)
2 48 (35.0) 36 (40.9)
3 75 (54.7) 42 (47.7)
Unknown 10 (7.3) 8 (9.1)
Site of metastases
Locoregional 45 (32.8) 28 (31.8)
Distant 117 (85.4) 78 (88.6)
Only locoregional 10 (7.3) 5 (5.7)
Only distant 82 (59.9) 55 (62.5)
Bones 54 (39.4) 37 (42.0)
Visceral 93 (67.9) 58 (65.9)
Number of metastatic sites
1 54 (39.4) 28 (31.8)
2 40 (29.2) 30 (34.1)
≥3 38 (27.7) 25 (28.4)
Unknown 5 (3.6) 5 (5.7)
History of 1st line CT 123 (89.8) 68 (77.3)
Anthracycline containing 18 (13.1) 9 (10.2)
Number of treatment lines with T
1 51 (37.2) 39 (44.3)
2 33 (24.1) 19 (21.6)
3 23 (16.8) 12 (13.6)
≥4 30 (21.9) 18 (20.5)
1p=0.019; CT chemotherapy, HT hormonal therapy, RT radiotherapy,
T trastuzumab.
HER2-positive: HER2 amplification by FISH and/or HER2 3+ by IHC.
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clinico-pathological parameters, such as age (>60 vs. 50–
60 vs. <50), menopausal status (post vs. pre), perform-
ance status (1–2 vs. 0), number of metastatic sites (≥3
vs. <3), anthracycline treatment (yes vs. no), hormonal
receptor status (ER/PgR) (positive vs. negative), Ki67
protein expression (high vs. low), HER2 status (positive
vs. negative), TOP2A gene status (deleted vs. non-
amplified vs. amplified) and TopoIIa protein expression
(positive vs. negative). Multivariate analyses were per-
formed in the total cohort and in the HER2-positive sub-
group and were presented by forest plots. All tests were
two-sided at the α=0.05 level of significance. No adjust-
ment for multiple comparisons was performed. Results
of this study were presented according to reporting
recommendations for tumor marker prognostic studies
[34]. The SPSS (version 15.0, IBM Corporation, Armonk,
NY) and SAS (version 9.3, SAS Institute Inc., Cary, NC)
software were used for statistical analysis.
Results
Among the 225 eligible patients with metastatic breast
cancer treated with trastuzumab, only 137 (61%) were
found to have centrally assessed HER2 gene amplifica-
tion by FISH and/or 3+ HER2 protein overexpression by
IHC (Figure 1). It is of note that all 225 patients were
considered to be HER2-positive when assessed with IHC
(and FISH in some cases) at the local laboratories and
had therefore been treated with trastuzumab. Selected
patient and tumor characteristics from the 225 patients,
at trastuzumab initiation, are presented in Table 1.
Trastuzumab was given as 1st line treatment in 191
patients (85%), while in 15% of the patients trastuzumab
was initiated later in the course of metastatic disease.
The majority of the 1st line treated patients received it in
combination with chemotherapy (186 patients, 97%), while
the rest (5 patients, 3%) received trastuzumab as mono-
therapy. Most of the patients received a taxane in the 1st
line setting in addition to trastuzumab (137 patients, 72%),
while 27 patients (14%) received anthracyclines.
Median follow-up for all patients was 66 months, while
for patients treated with trastuzumab in the 1st line median
follow-up was 51 months. Totally, 137 patients died among
all patients, while 151 of the 191 patients treated with tras-
tuzumab in the 1st line demonstrated tumor progression.
Median survival was significantly longer in HER2-positive
patients treated with trastuzumab (median survival 50.4
months, 95% Confidence Interval [CI]: 39.4-61.4) compared
to HER2-negative patients (median survival 35.3 months,
95% CI: 30.9-39.6, log-rank, p=0.007). TTP was 14 months
(95% CI: 9.6-18.5) for HER2-positive patients treated with
1st line trastuzumab, as compared to 10.3 months (95% CI:
5.6-15.0) for HER2-negative patients. This difference was
not statistically significant (log-rank, p=0.24), probably due
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PIK3CA data were presented in detail in a previous publica-
tion [22].
Associations between examined markers
TOP2A gene alterations were assessed in 221 tumors,
25% of which were amplified and 12% were deleted.
Tumors that were not TOP2A amplified or deleted were
analyzed as a separate group (TOP2A non-amplified
tumors). As expected, TOP2A gene amplification and
HER2-negative status were mutually exclusive. Represen-
tative FISH images of the evaluated cell lines and inva-
sive breast carcinoma cases are presented in Figure 2.
The majority of TOP2A gene deletions were seen in the
HER2-positive group (21 of the 26 cases), while 43% of
HER2-positive tumors were not amplified for TOP2A
(Table 2). A significant association of TOP2A gene status
with HER2 status was found (Fisher’s exact test,
p<0.001). Moreover, TOP2A gene amplification was more
frequent in ER-negative tumors (28% in ER-negative vs.
24% in ER-positive, p=0.017), whereas no such associ-
ation was found with Ki67 (p=0.47) or PTEN protein
expression (p=0.12). TOP2A gene amplification was
negatively associated with the presence of PIK3CA muta-
tions (28% in WT vs. 14% in mutated, p=0.035), the
distribution however, of PIK3CA mutations in the HER2-
positive group did not differ between TOP2A amplified
and non-amplified tumors (12% vs. 23%, p=0.25).
Concerning TopoIIa protein expression, the majority
of cases were positive (125 of 193 cases assessed, 65%),
but no association with HER2 status was found (p=0.65).
TopoIIa protein positivity was associated with ER-
positive status (72% in ER-positive vs. 49% in ER-negative,
p=0.005), high Ki67 expression (68% in high vs. 32% in
low, p=0.004) and positive PTEN protein status (80% in
positive vs. 58% in negative, p=0.003). The majority of the
PIK3CA mutations in this cohort (28 of 34) were encoun-
tered in tumors with positive TopoIIa protein expression
(p=0.015).
For 189 tumors, both TOP2A gene status and TopoIIa
protein expression were assessed (Figure 1), but no sig-
nificant association was found between the two (p=0.11).
More specifically, 37 among 49 TOP2A amplified tumors
were TopoIIa-positive (76%), while 73 among 117
TOP2A non-amplified tumors were TopoIIa-positive
(62%). TOP2A gene deletions were equally distributed
according to TopoIIa protein expression (11 TopoIIa-
negative cases vs. 12 TopoIIa-positive cases).
Effects of TOP2A gene alterations and TopoIIa protein
expression on the outcome of MBC patients treated
with trastuzumab
Survival analysis was performed in the 1st line treated
subpopulation (191 of the 225 patients treated withtrastuzumab), as defined in the statistical analysis sec-
tion. Since TOP2A gene amplification and HER2-
negativity were found to be mutually exclusive, we
examined in univariate analysis the association of
TOP2A gene status with outcome in the HER2-positive
subgroup only. TOP2A gene status was not associated
with TTP (Wald’s p=0.14), however, TOP2A non-
amplified and deleted tumors were associated with
increased risk for death (Hazard Ratio [HR]=2.16, 95%
CI: 1.20-3.88, Wald’s p=0.010 and HR=2.67, 95% CI:
1.27-5.62, p=0.009, respectively) compared to amplified
tumors (Table 3).
TopoIIa protein expression was not associated with ei-
ther TTP (Wald’s p=0.80 for HER2-positive and p=0.98
for HER2-negative patients) or survival (Wald’s p=0.22
for HER2-positive and p=0.30 for HER2-negative
patients). Tests for interaction of TopoIIa protein ex-
pression with HER2 status were not significant (Wald’s
p>0.05, for both TTP and survival). Interaction tests
of TOP2A gene status with HER2 status were not
applicable, since TOP2A gene amplification and HER2-
negativity were found to be mutually exclusive.
Since, subgroups defined by ER/PgR status are of clin-
ical interest, we also examined whether there was a sig-
nificant interaction between ER/PgR status and TOP2A
gene status or TopoIIa protein expression. No significant
interactions were found (Wald’s p values >0.05).
Interaction of TOP2A gene alterations with
anthracycline treatment
In the multivariate setting, we examined the predictive
role of TOP2A gene expression to anthracycline treat-
ment administered either in the adjuvant or the 1st line
metastatic setting. Ninety-three patients received anthra-
cyclines as adjuvant and/or 1st line treatment. The
majority of them (64 cases, 69%) were HER2-positive.
Concerning TOP2A gene expression in the anthracycline-
treated/HER2-positive subgroup, 25 patients were amp-
lified, 29 were non-amplified and 10 cases had a
TOP2A deletion.
In the HER2-positive subgroup, a significant inter-
action of TOP2A with anthracycline treatment (either in
the adjuvant or the 1st line setting) was observed both
for TTP (Wald’s p=0.055) and survival (Wald’s p=0.015),
while no clinicopathological parameters were retained in
the final model (Figure 3). In terms of TTP (Figure 3A),
among the TOP2A deleted subgroup, anthracycline-
treated patients were associated with increased risk for
progression, while in terms of survival (Figure 3B),
among the TOP2A amplified subgroup, anthracycline-
treated patients were associated with decreased risk for
death. No significant interactions were found between
TopoIIa protein expression and anthracycline treatment
(Wald’s p values >0.05).
Figure 2 Fluorescence in situ hybridization (FISH) in breast cancer cell lines and invasive breast carcinomas (IBC). FISH in breast cancer
cell lines (A-F) and IBC cases (G-L) for the HER2 and TOP2A genes using the HER2/TOP2A/CEN17 triple color probe. The MDA-MB-231 cell line
showed normal status of the HER2 and TOP2A genes (A-C), whereas in the SK-BR-3 cell line, co-amplification of the HER2 and TOP2A genes was
found (D-F). IBC case showing simultaneous amplification of the HER2 and TOP2A genes (G-I); IBC case with amplification of the HER2 gene,
deletion of the TOP2A gene and normal chromosome 17 status (J-L). Panels A, D, G and J show HER2 and centromere 17 hybridization signals;
Panels B, E, H and K show TOP2A and centromere 17 hybridization signals, where as panels C, F, I and L depict merged HER2, TOP2A and
centromere 17 signals. Magnification x1000.
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there were no significant differences in TTP between
deleted and non-amplified versus amplified tumors
(HR=0.76, 95% CI: 0.29-1.96, Wald’s p=0.57 and
HR=1.23, 95% CI: 0.61-2.47, p=0.56, respectively)(Figure 4A). For anthracycline-treated patients, deleted
and non-amplified tumors were associated with increased
risk for progression compared to amplified tumors
(HR=3.42, 95% CI: 1.57-7.46, Wald’s p=0.002 and
HR=1.83, 95% CI: 1.00-3.34, p=0.050, respectively)
Table 2 Association of TOP2A and TopoIIa with HER2 status
HER2 status Fisher’s exact p
Positive Negative
N % N %
TOP2A (FISH) n=221 Amplified 55 41.0 0 0 <0.001
Deleted 21 15.7 5 5.7
Non-amplified 58 43.3 82 94.3
TopoIIa (IHC) n=193 Negative 39 33.9 29 37.2 0.65
Positive 76 66.1 49 62.8
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ciations were observed. Among anthracycline-treated
patients, TOP2A deleted and non-amplified tumors had
increased risk for death compared to amplified tumors
(HR=6.94, 95% CI: 2.26-21.34, Wald’s p=0.001 and
HR=5.33, 95% CI: 2.02-14.12, p=0.001, respectively)
(Figure 4D). In patients not treated with anthracyclines no
such differences in survival were observed (Figure 4C). In
the contrary, no significant differences in TTP and
survival were observed between anthracycline- and non-
anthracycline-treated patients in the HER2-positive sub-
group when TOP2A gene status was not taken
into account (log-rank, p=0.67 for TTP and p=0.57
for survival).
Repeating the analysis in HER2-positive patients
that had received anthracyclines in the adjuvant setting
(52 of the 64 anthracycline-treated/HER2-positive
patients) the results were identical to the ones presented
in Figure 3. Among the TOP2A deleted subgroup, adju-
vant anthracycline-treated patients were associated with
increased risk for progression (HR=3.25, 95% CI: 1.16-
9.09, Wald’s p=0.025), while among the TOP2A ampli-
fied subgroup, adjuvant anthracycline-treated patientsTable 3 Univariate Cox regression models for TOP2A expressi
HER2-positive
Events HR 95% CI
TTP
TOP2A (FISH)
Deleted vs. Amplified 16 vs. 36 1.58 0.87-2.87
Non-amplified vs. Amplified 43 vs. 36 1.51 0.96-2.37
TopoIIa (IHC)
Positive vs. Negative 57 vs. 27 0.94 0.60-1.49
Survival
TOP2A (FISH)
Deleted vs. Amplified 12 vs. 17 2.67 1.27-5.62
Non-amplified vs. Amplified 33 vs. 17 2.16 1.20-3.88
TopoIIa (IHC)
Positive vs. Negative 38 vs. 19 0.71 0.41-1.24
CI confidence interval, HR hazard ratio, TTP time to progression.
Empty cells: Non-applicable.were associated with decreased risk for death (HR=0.27,
95% CI: 0.08-0.94, Wald’s p=0.041).
In multivariate analysis of the total cohort, the signifi-
cance of TOP2A in anthracycline-treated patients
remained, resulting in similar associations for both TTP
and survival (Additional file 1 and Additional file 2) to
the ones seen in the HER2-positive subgroup.
Finally, when examining in the models any TOP2A
alteration (deletions or amplifications) versus non-
amplification, the interaction with anthracycline treatment
was significant only in the case of the HER2-positive
subgroup in terms of survival (p=0.042), while among the
anthracycline-treated patients, tumors with TOP2A altera-
tions were associated with improved survival compared to
the non-amplified tumors.
Discussion
To our knowledge, the present study is one of the first
to evaluate the role of TOP2A gene amplification and
TopoIIa protein expression in the outcome of patients
treated with trastuzumab-based regimens for MBC.
The most important evidence provided herein is that
TOP2A gene amplification is a favorable prognosticon according to HER2 status
HER2-negative
Wald’s p Events HR 95% CI Wald’s p
0.13
0.07
0.80 31 vs. 17 1.01 0.55-1.83 0.98
0.009
0.010
0.22 23 vs. 14 0.70 0.36-1.37 0.30
Figure 3 Forest plots from multivariate Cox regression models in the HER2-positive patients. A: Time to progression (N=117). Among the
TOP2A deleted subgroup, anthracycline-treated patients were associated with increased risk for progression. B: Survival (N=117). Among the
TOP2A amplified subgroup, anthracycline-treated patients were associated with decreased risk for death.
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mab. Patients with HER2-positive/TOP2A non-amplified
or deleted tumors did not seem to benefit from
trastuzumab-based regimens and had an unfavorable out-
come compared to TOP2A amplified tumors, in line with
recent reports on TOP2A gene dosage [35] and TOP2A
gene amplification [36].
The role of the TOP2A gene has mainly been exam-
ined in relation to anthracycline treatment. Co-
amplification of HER2 and TOP2A was associated with
favorable response to anthracycline-based therapy of lo-
cally advanced breast cancer [12]. The results of our
study did not appear, at first, to be associated with the
administration of anthracyclines, since only 12% of our
patients had received such treatment in the 1st line
metastatic setting. However, 39% of all patients and 43%
of the HER2-positive ones had received anthracyclines
in the adjuvant setting. Upon further analysis of our
data, taking into account adjuvant and/or 1st line
anthracycline treatment, a significant interaction of
TOP2A with anthracycline treatment was observed both
for TTP and survival. In terms of survival among
the TOP2A amplified subgroup, anthracycline-treatedpatients were associated with decreased risk for death. It
appears therefore that the improvement in survival of
the TOP2A amplified subgroup treated with trastuzumab
is probably due to the concurrent or previous exposure
of the patients to anthracyclines, rather than the effect
of the trastuzumab treatment itself. Furthermore, when
TOP2A amplified patients treated with anthracyclines
in the adjuvant setting were analyzed separately, they
were found to have decreased risk for death, suggesting
that even history of adjuvant anthracycline treatment
results in survival advantage of TOP2A amplified patients
treated with trastuzumab.
There is a very recent report from the Breast Cancer
International Research Group (BCIRG) 006 trial [37]
and an additional retrospective analysis of almost
5,000 patients [13] regarding the efficacy of trastuzumab
in breast cancer patients with HER2 and TOP2A co-
amplification. The first study is one of the largest rando-
mized trials, which confirmed the role of trastuzumab
in the adjuvant setting. The most interesting aspect
of the BCIRG 006 trial is that it included a non-
anthracycline regimen (docetaxel, carboplatin and tras-
tuzumab), which was compared to AC-T (doxorubicin,
Figure 4 Kaplan-Meier curves according TOP2A gene status and anthracycline treatment. Time to progression (TTP, A-B) and survival (C-D)
according to TOP2A gene status in the HER2-positive patients stratified by anthracycline treatment.
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without trastuzumab. This study demonstrated that
the DFS benefit conferred by AC-T without trastuzumab
in HER2-positive breast cancer patients is actually
restricted to TOP2A co-amplified malignancies, which
constituted a subset (35%) of the HER2-positive cancers,
and is virtually indistinguishable from the benefit
achieved by the addition of trastuzumab. Importantly,
this same benefit (found in the TOP2A co-amplified sub-
set) could also be attained by a non-anthracycline regi-
men in combination with trastuzumab, thus avoiding the
toxicities seen with anthracyclines. In our study, trastu-
zumab was given to advanced-stage HER2-positive
breast cancer patients in the metastatic setting, our find-
ings should not therefore be compared to those of the
BCIRG 006 trial [37].
Recent studies support the role of TopoIIa pro-
tein expression, rather than TOP2A gene amplification,
as a predictor of response to anthracycline-basedchemotherapy in the adjuvant setting [16]. It is of note,
that TopoIIa protein overexpression has been reported
in HER2-positive, as well as HER2-negative tumors,
independently of TOP2A gene amplification [38]. The
latter finding has also been shown in our study; TopoIIa
protein overexpression however, was not associated with
either TTP or survival.
TopoIIa protein overexpression was however asso-
ciated with ER-positive status and high Ki67 expression,
partly in line with previous reports, since TopoIIa pro-
tein expression had been shown to be associated with
ER-positive status [39] and the Ki67 proliferation index
[40]. To the best of our knowledge, the associations
between TopoIIa and PTEN protein expression, as well
as PIK3CA mutation presence are new findings in breast
cancer tissue series, meriting further investigation for
their biological importance. Of note, TopoIIa protein is
upregulated in proliferating normal and cancer cells, in
order to participate in the cell duplication process [41].
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plastic cells to assess TopoIIa protein positivity, tumors
are found to be positive for TopoIIa in the absence of
underlying amplification of the corresponding gene.
Alterations of the TOP2A gene mostly happen in
HER2-positive tumors, however TOP2A does not always
follow the amplification fate or rate of the HER2 ampli-
con, since it is not always included in the so called
“smallest region of amplification” next to HER2 [36,42],
while it may also be deleted in the presence of HER2
amplification, as observed here and elsewhere [10].
Thus, at least in a subset of TOP2A amplified tumors,
the mechanism driving TOP2A amplification may be dif-
ferent than the one resulting in HER2 amplification
[9,10,43], as shown by the far lower ratio of TOP2A
signals in comparison to HER2 signals [10]. In addition,
TOP2A may also be amplified or deleted in the absence
of HER2 amplification, further supporting the view of
distinct and possibly multiple mechanisms, resulting in
alterations of this gene. The absence of TOP2A amplifi-
cation and the presence of deletions may practically have
the same unfavorable impact on the outcome of HER2-
positive patients, as shown in this study. With respect to
gene deletions, it should be noted that the way markers
are scored with FISH on FFPE sections it is unavoidable
to obtain false positive results (deletions), due to nuclear
truncations that interfere with the number of fluorescent
signals to be counted per nucleus in a mostly unpredict-
able manner. Hence, although TOP2A gene deletions
may indeed occur, the results concerning this FFPE-
FISH marker, in the present and in the previously pub-
lished studies, should be interpreted with caution.
In most of the published series, TOP2A gene amplifi-
cation or deletion was a rare event in HER2-negative
patients [44]. Only in four studies [10,16,18,45], the rate
of TOP2A alterations was considerably greater than the
1% to 2% range reported in all other studies. In line with
the majority of the published data we did not find
HER2-negative patients with TOP2A gene amplification.
Conclusions
In conclusion our study is one of the first to examine
the role of the TOP2A gene in the field of trastuzumab-
based treatment in MBC. We have evaluated the role of
TOP2A gene amplification and TopoIIa protein expres-
sion and we have shown that TOP2A gene amplifica-
tion is a favorable prognostic factor in HER2-positive
MBC patients treated with trastuzumab, such an effect
however, appears to rather be related to treatment with
anthracyclines. In advanced-stage HER2-positive breast
cancer patients treated with trastuzumab, TOP2A ampli-
fication appears to be a strong predictive factor for
improved survival in patients with concurrent or pre-
vious exposure to anthracyclines. Nevertheless, given thesmall size and the retrospective nature of our study,
these data have to be viewed as hypothesis generating
and need to be further explored and validated in larger
cohorts of patients treated in the context of randomized
trials. We are currently investigating these associations
in patients included in a large adjuvant phase III trial
conducted by our Group.
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